Clinical Metabolomics Inc.
Sharpening clinical trials with metabolomics
This article was originally published in Start Up
Pharma has had trouble developing therapeutics for diabetic kidney disease because of its slow disease process – it can take months or years to demonstrate an improvement in kidney function in response to a drug. Researchers at Clinical Metabolomics Inc. (doing business as ClinMet) think their technology for monitoring kidney function through metabolites found in the urine can speed clinical trials by identifying signs of kidney improvement, and the research also has led to a new insight into the underlying causes of DKD that could lead to new therapies.
You may also be interested in...
Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.
X4 Pharmaceuticals Inc. spun out from Sanofi to develop compounds that target the CXCR4/CXCL12 receptor pathway to restore immune cell surveillance against cancer.
Over the past five years, pharma companies have cast an increasingly wide research net in search of cancer immunotherapy drug combinations that can help patients who have failed monotherapies.